{
    "info": {
        "nct_id": "NCT05243797",
        "official_title": "Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4",
        "inclusion_criteria": "* Must have a new diagnosis of multiple myeloma according to IMWG criteria and have received induction +/- consolidation.\n* Must have received only one line of therapy and achieved at least a partial response (≥PR) as per IMWG 2016 response criteria (Kumar 2016) without evidence of progression at the time of first treatment dose.\n* Must not be intolerant to the starting dose of lenalidomide.\n* Must not have received any maintenance therapy.\n* Have an ECOG performance status score of 0, 1, or 2 at screening and immediately prior to the start of administration of study treatment\n* Have clinical laboratory values within prespecified range.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Received any prior BCMA-directed therapy.\n* Any previous therapy with an immune cell redirecting agent or gene modified adoptive cell therapy (eg, chimeric antigen receptor modified T cells, NK cells).\n* Discontinued treatment due to any AE related to lenalidomide as determined by the investigator.\n* Progressed on multiple myeloma therapy at any time prior to screening.\n* Received a cumulative dose of corticosteroids equivalent to ≥140 mg of prednisone within the 14 days prior to first treatment dose.\n* Received a live, attenuated vaccine within 4 weeks before first treatment dose. Non-live vaccines or non-replicating authorized for emergency use (eg. COVID-19) are allowed.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Must have a new diagnosis of multiple myeloma according to IMWG criteria and have received induction +/- consolidation.",
            "criterions": [
                {
                    "exact_snippets": "Must have a new diagnosis of multiple myeloma according to IMWG criteria",
                    "criterion": "multiple myeloma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_status",
                            "expected_value": "new"
                        },
                        {
                            "requirement_type": "diagnostic_criteria",
                            "expected_value": "IMWG"
                        }
                    ]
                },
                {
                    "exact_snippets": "have received induction +/- consolidation",
                    "criterion": "prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment_received",
                            "expected_value": [
                                "induction",
                                "consolidation (optional)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have clinical laboratory values within prespecified range.",
            "criterions": [
                {
                    "exact_snippets": "clinical laboratory values within prespecified range",
                    "criterion": "clinical laboratory values",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": "within prespecified range"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have an ECOG performance status score of 0, 1, or 2 at screening and immediately prior to the start of administration of study treatment",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status score of 0, 1, or 2 at screening and immediately prior to the start of administration of study treatment",
                    "criterion": "ECOG performance status score",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1",
                                "2"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "at screening",
                                "immediately prior to the start of administration of study treatment"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must not have received any maintenance therapy.",
            "criterions": [
                {
                    "exact_snippets": "Must not have received any maintenance therapy",
                    "criterion": "maintenance therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must have received only one line of therapy and achieved at least a partial response (≥PR) as per IMWG 2016 response criteria (Kumar 2016) without evidence of progression at the time of first treatment dose.",
            "criterions": [
                {
                    "exact_snippets": "Must have received only one line of therapy",
                    "criterion": "number of prior lines of therapy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "achieved at least a partial response (≥PR) as per IMWG 2016 response criteria (Kumar 2016)",
                    "criterion": "treatment response according to IMWG 2016",
                    "requirements": [
                        {
                            "requirement_type": "response category",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "partial response (PR)"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without evidence of progression at the time of first treatment dose",
                    "criterion": "disease progression status at time of first treatment dose",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must not be intolerant to the starting dose of lenalidomide.",
            "criterions": [
                {
                    "exact_snippets": "Must not be intolerant to the starting dose of lenalidomide",
                    "criterion": "intolerance to starting dose of lenalidomide",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Received a cumulative dose of corticosteroids equivalent to ≥140 mg of prednisone within the 14 days prior to first treatment dose.",
            "criterions": [
                {
                    "exact_snippets": "Received a cumulative dose of corticosteroids equivalent to ≥140 mg of prednisone within the 14 days prior to first treatment dose.",
                    "criterion": "cumulative corticosteroid dose",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 140,
                                "unit": "mg prednisone equivalent"
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within the 14 days prior to first treatment dose"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received any prior BCMA-directed therapy.",
            "criterions": [
                {
                    "exact_snippets": "Received any prior BCMA-directed therapy",
                    "criterion": "prior BCMA-directed therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Progressed on multiple myeloma therapy at any time prior to screening.",
            "criterions": [
                {
                    "exact_snippets": "Progressed on multiple myeloma therapy at any time prior to screening.",
                    "criterion": "progression on multiple myeloma therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "any time prior to screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any previous therapy with an immune cell redirecting agent or gene modified adoptive cell therapy (eg, chimeric antigen receptor modified T cells, NK cells).",
            "criterions": [
                {
                    "exact_snippets": "Any previous therapy with an immune cell redirecting agent",
                    "criterion": "previous therapy with immune cell redirecting agent",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Any previous therapy with ... gene modified adoptive cell therapy (eg, chimeric antigen receptor modified T cells, NK cells)",
                    "criterion": "previous therapy with gene modified adoptive cell therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Discontinued treatment due to any AE related to lenalidomide as determined by the investigator.",
            "criterions": [
                {
                    "exact_snippets": "Discontinued treatment due to any AE related to lenalidomide as determined by the investigator.",
                    "criterion": "treatment discontinuation due to lenalidomide-related adverse event",
                    "requirements": [
                        {
                            "requirement_type": "cause",
                            "expected_value": "adverse event related to lenalidomide"
                        },
                        {
                            "requirement_type": "determination",
                            "expected_value": "as determined by the investigator"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received a live, attenuated vaccine within 4 weeks before first treatment dose. Non-live vaccines or non-replicating authorized for emergency use (eg. COVID-19) are allowed.",
            "criterions": [
                {
                    "exact_snippets": "Received a live, attenuated vaccine within 4 weeks before first treatment dose",
                    "criterion": "live, attenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "vaccine type",
                            "expected_value": "live, attenuated"
                        }
                    ]
                },
                {
                    "exact_snippets": "Non-live vaccines or non-replicating authorized for emergency use (eg. COVID-19) are allowed",
                    "criterion": "non-live or non-replicating vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "authorization status",
                            "expected_value": "authorized for emergency use"
                        },
                        {
                            "requirement_type": "vaccine type",
                            "expected_value": [
                                "non-live",
                                "non-replicating"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}